Clinical trial
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or…
NCT00045110 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00045110 |
|---|---|
| Title | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma |
| Official title | A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 136 |
| Start date | Aug 1, 2002 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 17, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: